Navigation Links
Gene therapy anti-cancer research featured in Scientific American
Date:8/22/2008

BIRMINGHAM, Ala. Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies.

David T. Curiel, M.D., Ph.D., is a UAB professor of medicine and director of the human gene therapy division, and Ronald Alvarez, M.D., is a UAB professor of medicine and director of the gynecologic oncology division.

Both doctors are featured in a Scientific American special cancer edition, and both served as co-authors on the story "Tumor-busting viruses." The editors chose Curiel and Alvarez because of their research into a field called viral gene therapy, or virotherapy.

Virotherapy involves an experimental technique to target viruses to cancer cells while leaving healthy cells untouched. The viruses are genetically engineered to kill tumor cells in different ways. One way is by adopting the viruses' natural ability to invade and reproduce as a way to deliver target genes that make tumor cells more susceptible to existing chemotherapies.

Curiel and Alvarez have been testing this concept with a virus compound called adenovirus in women with recurrent ovarian or other gynecological cancers. The clinical trial is still in the early stages, yet the compound has shown anti-tumor effects that appear safe to most patients, Curiel said.

"We envision a substantial role for viruses that is, therapeutic viruses in 21st-century medicine," Curiel and Alvarez wrote in wrote in the story.

First proposed in the 1940s, virotherapy now relies heavily on adenoviruses, a cause of the common cold that has been studied and altered extensively for medical research. Adenoviruses have the ability to shuttle targeted segments of DNA into a tumor cell and make biochemical changes that minimize damage to healthy cells.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Page: 1

Related biology news :

1. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
2. Immunotherapy in high-risk pediatric sarcomas shows promising response
3. Anti-HIV therapy boosts life expectancy more than 13 years
4. Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings
5. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
6. Prostate cancer vaccines more effective with hormone therapy
7. New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
8. Caution on stem cell therapy
9. Potential therapy discovered for hypophosphatasia, a congenital form of rickets
10. UF researchers develop improved gene therapy agent
11. Gene therapy slows progression of fatal neurodegenerative disease in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology: